Company Overview and News

Patanjali in talks with VCs for funds

New Delhi : Baba Ramdev-led Patanjali Ayurved Ltd is in talks with several foreign funds for capital for its ongoing projects, like food processing and manufacturing units, said a company official. The Haridwar-based company, looking to raise Rs 5,000 crore, has held several meetings with leading fund managers in Mumbai in the last couple of months through financial services company UBS and IDFC. Patanjali MD Acharya Balkrishna also participated in the meetings, he added.

Net1 launches one of the world's largest virtual card programs with MobiKwik and IDFC Bank

2017-11-09 marketwired
Over 260 million users will eventually have access to MobiKwik's virtual Visa prepaid card in phases, with 65 million existing users part of the first phase

Mumbai: To develop roads in Maharashtra, state eyeing for global funding

Mumbai: To develop around 10,000 km of the state highways under the rejuvenation project, the Maharashtra government is hoping to catch the eye of some of the biggest global investors.

Health dept ropes in BMC to check spread of diseases

Bhopal: After the incessant rains ravaged the state capital, health department has started working on measures to control spread of diseases especially in areas which were submerged in water. CMHO Dr Veena Sinha has ordered immediate action to clean the areas where water-logging has created accumulation of dirt. “We have coordinated with Bhopal Municipal Corporation in this regard and they have already started their work.

RBI to cut rates only if inflation ebbs: Mundra on CPI data

Mumbai:  After an upward swing in May inflation, RBI Deputy Governor S S Mundra said the central bank will continue to monitor data and slash rates only if there is a decline in the number.  “…All the data points will be taken into account. If any room develops, then there would be room for the accommodative monetary policy to continue,” Mundra said. He was replying to a question on CPI data for May.

RBI Dy Guv says no space for ‘adventurism’ for new banks

RBI would maintain a close watch on newly licensed banks in the initial years; Mundra also crititicises those who exited the payments bank space after getting in-principle licences

IDFC FY16 loss at Rs 935 crore

2016-04-30 financialexpress
IDFC on Friday reported a consolidated net loss of Rs 934.8 crore for FY16, compared with a profit of Rs 1,706.9 crore in the previous year, having made a special provision for Rs 2,638.7 crore in the second quarter.

With roads cleared, SMS to exit project

2016-02-24 financialexpress
SMS Shivnath Infrastructure (SMSSIL) — one of the first road projects awarded on the build, operate and transfer (BOT) model by National Highways Authority of India...

IDFC Alternatives, I Squared eye two Gayatri projects

2016-02-23 financialexpress
IDFC Alternatives and I Squared Capital are in the race for acquiring a controlling stake in two projects of Gayatri Projects, according to sources familiar...

IDFC Bank sees bad loans rising, no impact on earnings

2016-01-27 in.reuters
MUMBAI IDFC Bank Ltd, one of India's two newest banks, expects its gross bad loans to increase in the coming quarters although that will not hit earnings as it has made adequate provisions, it said on Wednesday.

IDFC Bank Q3 net at Rs 242 cr

2016-01-27 business-standard
IDFC Bank that announced its first quarterly earnings after listing on the bourses has reported a net profit of Rs 242.2 cr in Oct-Dec quarter

Q3 profit of IDFC bank stands at Rs 242 crore

2016-01-27 financialexpress
In its first quarterly numbers, IDFC Bank posted Rs 242.16 crore profit for the three months ended December 31, 2015.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...